Qvella is a molecular diagnostics company founded by a group of scientists and engineers with the simple goal of dramatically reducing time to results in bacteriology. This objective, widely recognised as higly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practised by slashing costs and saving lives. Qvella’s Field Activated Sample Treatment (FAST ) technology utilises a novel electrical lysing and sample treatment technique enabling rapid detection of infectious agents in a direct blood sample. When implemented in concert with Antibiotic Stewardship programs, now being adopted by most major medical centers, timely clinical decisions can be made which lead to improved patient outcomes, reduced hospital stays, lower side effect profiles, and a significant reduction in treatment costs.